Your session is about to expire
← Back to Search
Study Summary
This trial will study how different degrees of liver damage affect the way a person's body processes a drug called PF-07081532.
- Liver Disease
- Healthy Subjects
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 trial • 66 Patients • NCT04305587Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Could you provide an update on the current enrollment status of this research endeavor?
"As demonstrated by clinicaltrials.gov, this research trial is actively seeking volunteers. The study's initial posting was on August 1st 2022 and the most recent update happened October 10th of that same year."
How many volunteers are taking part in the clinical experiment?
"Affirmative. The information provided on clinicaltrials.gov attests that this medical study is currently recruiting patients, which was initially posted on August 1st 2022 and recently updated October 10th 2022. 24 participants are required from three particular sites for enrolment in the trial."
Is eligibility for the trial limited to people aged 20 and under?
"This particular clinical trial has set the upper age limit to 70 and a lower limit of 18. Additionally, there are 77 studies available for minors while 589 are accessible to those over 65 years old."
Could I enroll in this medical research project?
"This medical trial is recruiting 24 patients that have hepatic impairment and reside between the ages of 18 to 70. Those interested must fulfill these criteria in order to be considered for participation."
Could you elucidate the risks associated with PF-07081532 administration?
"Based on the limited data available for PF-07081532, Power has established a safety rating of 1. This is because this product is currently at Phase 1 and does not have substantial evidence supporting its efficacy or lack thereof."
Share this study with friends
Copy Link
Messenger